Company establishes EMEA Headquarters in Lucerne
Novocure is a commercial-stage oncology company dedicated to the advancement of TTF therapy (Tumor Treating Fields) for patients with solid tumors. The company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-cancer therapy.
Since 2000, the company has grown from one inspired man running experiments in his basement lab to the multinational commercial business it is today. Headquartered in St. Helier, Jersey, Novocure has US operations across New Hampshire, Pennsylvania, and New York as well as their EMEA HQ in Lucerne, Switzerland, among operations in other countries.
Specifically at Lucerne’s EMEA Headquarters, Novocure spearheads its Global Clinical Research activities as well as its Global Supply Chain & Logistics, distributing its product to the EMEA markets. The company employs approximately 100 people in Lucerne, Switzerland.
“In Root, Lucerne, we found the ideal base for our operations in Europe. We have the flexibility to quickly expand our business by adding qualified people, and by increasing office and warehouse space.”
Thomas Hefti, VP Europe and Emerging Markets
Novocure recently released a press release announcing that effective April 1, 2021, the Swiss Federal Office of Public Health has added Optune, Novocure’s cancer therapy device, to the list of medical devices covered by health insurance in Switzerland.
“We are extremely pleased that Switzerland has established national reimbursement for Optune,” said Thomas Hefti, Vice President Europe and Emerging Markets (EMEA). “Access to our therapy continues to grow throughout the world, demonstrating health insurers’ increasing recognition of Optune.”
Read more from Lucerne Business below.